The Latest Breaking News on Pharma

India must invest substantially more in fundamental research to incubate the local drug industry into the future

The biotech industry’s growth prospects look promising due to considerable investments in research and development (R&D), an innovative drugs pipeline, government initiatives, the growing popularity of personalized medicine, drug approvals, expanding healthcare needs, etc. Amid this backdrop, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX),…

Initiatives like GoodRx and Sempre Health are working towards transparency and affordability in the drug supply chain to improve medication adherence. Blue...

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

The biotechnology industry is experiencing significant growth, fueled by government initiatives, rising investments and tech advancements. Therefore, it could be wise to consider fundamentally strong biotech stocks Shionogi & Co (SGIOY), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), which are making major moves on wall street. Read more.

InMode stock skidded Tuesday as high interest rates weighed on the aesthetics company's sales. Shares fell to a floor near their 50-day line.

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

Among the best stocks to buy and watch, Intra-Cellular Therapies is approaching a new buy point ahead of its earnings results.

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….